Milestone Pharmaceuticals Inc — Cash Flow (NASDAQ:MIST) | MetaTrader

Open full chart

Financials

Overview 声明 Statistics Dividends

Quarterly Annual

Cash from operating activities 50.73 M33.22 M52.47 M46.42 M28.85 M 43.11 M Cash from investing activities 70 M70 M57.12 M4.76 M8.28 M 5.78 M Cash from financing activities 73.22 M5.05 M3.09 M47.79 M32.12 M 49.12 M Free cash flow 50.73 M33.22 M52.2 M46.31 M28.82 M 43.09 M

新闻

Milestone Pharmaceuticals appoints David Sandoval as general counsel

All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy

Milestone’s PSVT treatment CARDAMYST now available in US pharmacies

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST)

Aptar的鼻腔喷雾系统将用于递送新获批的PSVT治疗药物

Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher (MIST)

TD Cowen上调Milestone Pharmaceuticals评级至买入，因FDA批准上市

Milestone Pharmaceuticals stock rating upgraded by TD Cowen to Buy on FDA approval

Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment - Slideshow (NASDAQ:MIST) 2025-12-15

里程碑制药股价飙升，FDA批准首款自用PSVT鼻喷剂

Milestone stock soars after FDA approves first self-administered PSVT spray

Why Is Milestone Pharmaceuticals Stock Skyrocketing Monday? - Milestone Pharmaceuticals (NASDAQ:MIST)